In addition, SGLT2 inhibitors exhibit an insulin-independent mode of action, rendering them suitable for use in patients with varying degrees of insulin resistance and type 2 diabetes mellitus (T2DM) [5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.